Return to homepagePandemic Pact

Development of a defective interfering RNA based antiviral approach to treat infections by SARS-CoV-2 and emerging variants

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:3 publications

Grant number: 2011398

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Known Financial Commitments (USD)

    $603,914.24

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    Assoc Prof David Harrich

  • Research Location

    Australia

  • Lead Research Institution

    QIMR Berghofer Medical Research Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Specific therapy for severe disease caused by SARS-CoV-2 is limited. The ability of viruses to become resistant to a therapy may be obstacle for antiviral development. This project develops a unique platform, using virus-specific antiviral RNA, as a unique and possibly "antiviral-resistance" proof approach that could be deployed as a therapeutic for COVID-19 and also help to solve the challenge of viral pandemics from known and unknown viruses, especially other human pathogenic coronaviruses.

3 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Turning defects into defenses: the potential and challenges of defective viral genome-based antiviral strategies.

Reprogramming chemoimmunotherapy via biomimetic cell membrane- clay platform to amplify prime-boost antitumor immunity.

Defective Interfering Particles with Broad-Acting Antiviral Activity for Dengue, Zika, Yellow Fever, Respiratory Syncytial and SARS-CoV-2 Virus Infection.